[907] CANSEARCH Research Laboratory

Recherche-Ansari.gif

The group works manly on two topics in 2013

Pharmaco-oncogenetics

Prof. Marc Ansari worked in the field of pediatric oncogenetics at the St Justine Hospital (Montréal, Canada) between 2004 and september 2007 thanks to the financial support of the Swiss National Science Foundation. In 2007 he joinedthe CMU, where he continued his research on the polymorphism of certain genes involved in the metabolism of Busulfan, the main chemotherapeutic agent used in hematopoietic stem cell transplantation. He could demonstrate that the genetic polymorphisms in certain genes that control the enzymes involved in the metabolism of Busulfan are responsible for the efficiency and the toxicity of this agent. This project has been accepted as a multicentric study by the European Group for Blood and Marrow Transplantation (EBMT).  These scientific works allow for decreasing drug toxicity and increasing outcome in children with cancer. Thanks to these works, medication can be adapted according to specific genes (individualized therapy).

Oncogenetics

The group works as well on the ATM (Ataxia Telangiectasia Mutated) tumor suppressor gene. Through collaboration with the Children’s Oncology Group (USA) Dr Gumy-Pause obtained a large number of tumor samples necessary to her research. At first, her work focused on leukemia and lymphoma in childhood (mainly thanks to the support of the Dubois-Ferrière-Dinu Lipatti Foundation), then on neuroblastoma. She could demonstrate that in neuroblastoma, ATM loss occurs frequently and, in addition, is a likely marker of bad prognosis. On the long-term, the aim of her research work is to adapt the treatment to the genotype of the tumor and to develop new therapeutic strategies.

Prof.  Ansari created the CANSEARCH foundation to support his research laboratory. For more informations and to find annual report please visit www.cansearch.ch

Group Publications